As a positive trend, we identified cases beyond oncology and pediatric conditions, showing the potential for RWE to support regulatory approval of drugs in other therapeutic areas (e.g., epilepsy, diabetes, or rheumatoid arthritis).
← all excerpts
The Evidence REVEAL Study: Exploring the Use of Real-World Evidence and Complex Clinical Trial Design by the European Pharmaceutical Industry.
1
—
—